Retirement Systems of Alabama Sells 1,067 Shares of Repligen Co. (NASDAQ:RGEN)

Retirement Systems of Alabama lowered its holdings in Repligen Co. (NASDAQ:RGEN) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 64,137 shares of the biotechnology company’s stock after selling 1,067 shares during the quarter. Retirement Systems of Alabama owned about 0.11% of Repligen worth $8,085,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. YHB Investment Advisors Inc. acquired a new stake in shares of Repligen in the first quarter valued at approximately $26,000. Lazard Asset Management LLC boosted its position in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 146 shares during the period. Principal Securities Inc. bought a new stake in shares of Repligen during the fourth quarter worth $48,000. Finally, GAMMA Investing LLC lifted its stake in shares of Repligen by 183.4% during the second quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 310 shares during the period. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Anthony Hunt purchased 2,000 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was purchased at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the acquisition, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The disclosure for this purchase can be found here. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

Shares of RGEN stock opened at $146.80 on Friday. The firm has a market capitalization of $8.20 billion, a price-to-earnings ratio of 587.20, a price-to-earnings-growth ratio of 5.27 and a beta of 0.95. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a fifty day moving average of $138.66 and a 200-day moving average of $162.89.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 earnings per share. On average, equities research analysts forecast that Repligen Co. will post 1.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $190.00 price objective on shares of Repligen in a report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Guggenheim assumed coverage on Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.57.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.